1stOncology™: Cancer Intelligence Service – Page 11230 – 1stOncology is recognized as a Top 10 Global Pharma Analytic Provider

TRACON Pharmaceuticals To Present At The Wells Fargo Virtual Healthcare Conference

On September 3, 2020 TRACON Pharmaceuticals (Nasdaq: TCON), a clinical stage biopharmaceutical company focused on the development and commercialization of novel targeted cancer therapeutics and utilizing a cost efficient, CRO-independent product development platform to partner with ex-U.S. companies to develop and commercialize innovative products in the U.S., reported that Charles Theuer, M.D., Ph.D., President and CEO, will present a corporate overview at the 2020 Wells Fargo Virtual Healthcare Conference on Wednesday, September 9th, at 10:40 am EDT (Press release, Tracon Pharmaceuticals, SEP 3, 2020, View Source [SID1234564418]).

Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:

Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing

Schedule Your 30 min Free Demo!

To access a live webcast of the presentation, please visit the "Events and Presentations" page within the "Investors" section of the TRACON Pharmaceuticals website at www.traconpharma.com.

Seattle Genetics to Present at the Morgan Stanley 18th Annual Global Healthcare Conference

On September 3, 2020 Seattle Genetics, Inc. (Nasdaq:SGEN) reported that management will participate in a fireside chat during the virtual Morgan Stanley 18th Annual Global Healthcare Conference on Tuesday, September 15, 2020 at 3:30 p.m. Eastern Time (Press release, Seattle Genetics, SEP 3, 2020, View Source [SID1234564416]). The presentation will be webcast live and available for replay from Seattle Genetics’ website at www.seattlegenetics.com in the Investors section.

BIO-TECHNE TO PRESENT AT THE 2020 WELLS FARGO VIRTUAL HEALTHCARE CONFERENCE

On September 3, 2020 Bio-Techne Corporation (NASDAQ:TECH) reported that Chuck Kummeth, President and Chief Executive Officer, will present at the 2020 Wells Fargo Virtual Healthcare Conference on Wednesday, September 9, 2020 at 11:20 a.m. EDT (Press release, Bio-Techne, SEP 3, 2020, View Sourcepress-releases/detail/207/bio-techne-to-present-at-the-2020-wells-fargo-virtual" target="_blank" title="View Sourcepress-releases/detail/207/bio-techne-to-present-at-the-2020-wells-fargo-virtual" rel="nofollow">View Source [SID1234564415]). A live webcast of the presentation can be accessed via Bio-Techne’s Investor Relations website at View Source or through the following link (webcast).

TLC to Present at Baird’s 2020 Global Healthcare Conference

On September 3, 2020 TLC (Nasdaq: TLC, TWO: 4152), a clinical-stage specialty pharmaceutical company developing novel nanomedicines to target areas of unmet medical need, reported that George Yeh, President of TLC, will be presenting the latest updates on the company in a fireside chat with Madhu Kumar, Senior Research Analyst, at Baird’s 2020 Global Healthcare Conference on Wednesday, September 9, 2020 at 8:30am ET (Press release, Taiwan Liposome Company, SEP 3, 2020, View Source [SID1234564414]).

The 30-minute fireside chat will include a company overview followed by a Q&A session. During the conference, which is taking place virtually September 9-10, 2020, TLC will also be participating in one-on-one sessions. While the fireside chat is only accessible to Baird clients registered for the event, a corporate presentation entailing the updates will be available on the company’s website at www.tlcbio.com under the Investors section.

Entry into a Material Definitive Agreement.

On September 2, 2020,Idera Pharmaceuticals reported that the Company and Lincoln Park entered into a First Amendment to Purchase Agreement (the "Amended Purchase Agreement") (Filing, 8-K, Idera Pharmaceuticals, SEP 2, 2020, View Source [SID1234564413]). The primary purpose of the Amended Purchase Agreement was to reference the Company’s Registration Statement on Form S-3, Registration No. 333-240366 (the "Registration Statement"), rather than the registration statement that had been referenced at the time of the Purchase Agreement, and facilitate a corresponding increase in the number of shares of Common Stock issuable under the Exchange Cap (as defined in the Amended Purchase Agreement). The Amended Purchase Agreement limits the Company’s sale of shares of Common Stock to Lincoln Park from the date thereof to 7,036,329 shares of Common Stock, representing 19.99% of the shares of the Common Stock outstanding on the date of the Amended Purchase Agreement unless (i) shareholder approval is obtained to issue more than such amount or (ii) the average price of all applicable sales of Common Stock to Lincoln Park under the Amended Purchase Agreement equals or exceeds $2.05 per share, which represents the lower of (A) the closing price of the Common Stock on the Nasdaq Capital Market immediately preceding the date of the Amended Purchase Agreement or (B) the average of the closing prices of the Common Stock on the Nasdaq Capital Market for the five Business Days immediately preceding the date of the Amended Purchase Agreement, as calculated in accordance with Nasdaq Rules.